Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial.

[1]  J. Bonneterre,et al.  Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2 , 2012, British Journal of Cancer.

[2]  H. Linden,et al.  Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Desilvio,et al.  A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC). , 2011 .

[4]  J. Bonneterre,et al.  Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients , 2011, Cancer Chemotherapy and Pharmacology.

[5]  B. Karaszewska,et al.  A phase II randomized trial of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC). , 2010 .

[6]  E. Perez,et al.  Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. , 2008, Mayo Clinic proceedings.

[7]  J. Baselga,et al.  Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU) , 2008 .

[8]  A. D. Van den Abbeele,et al.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  柏葉 匡寛.  What's going on HER2過剰発現転移性乳がんに対するトラスツズマブとビノレルビンあるいはタキサン併用療法試験[Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP 'Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane , 2007 .

[10]  E. Winer,et al.  Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study , 2007, Cancer.

[11]  J. O’Shaughnessy,et al.  Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. , 2007, Clinical breast cancer.

[12]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[13]  H. Sommer,et al.  Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial , 2006, British Journal of Cancer.

[14]  M. Ellis,et al.  Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Suter,et al.  Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. , 2004, Breast.

[16]  J. Mortimer,et al.  Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. , 2002, The oncologist.

[17]  J. Manola,et al.  Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  I. Smith,et al.  Vinorelbine – a clinical review , 2000, British Journal of Cancer.

[19]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.